TY - JOUR
T1 - Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer
AU - Zhang, Xiaozhu
AU - Chang, Alex
PY - 2008/7/11
Y1 - 2008/7/11
N2 - The epidermal growth factor receptor (EGFR) is overexpressed in the majority of non-small cell lung cancers (NSCLC) and is a major target for new therapies. Specific EGFR tyrosine kinase inhibitors (TKIs) have been developed and used for the treatment of advanced NSCLC. The clinical response, however, varies dramatically among different patient cohorts. Females, East Asians, non-smokers, and patients with adenocarcinoma usually show higher response rates. Meanwhile, a number of biological factors are also associated with EGFR-TKIs responsiveness. In order to better understand the predictive value of these biomarkers and their significance in clinical application we prepared this brief review. Here we mainly focused on EGFR somatic mutations, MET amplification, K-ras mutations, EGFRvIII mutation, EGFR gene dosage and expression, HER2 gene dosage and expression, and Akt phosphorylation. We think EGFR somatic mutation probably is the most effective molecular predictor for EGFR-TKIs responsiveness and efficacy. Mutation screening test can provide the most direct and valuable guidance for clinicians to make decision on EGFR-TKIs therapy.
AB - The epidermal growth factor receptor (EGFR) is overexpressed in the majority of non-small cell lung cancers (NSCLC) and is a major target for new therapies. Specific EGFR tyrosine kinase inhibitors (TKIs) have been developed and used for the treatment of advanced NSCLC. The clinical response, however, varies dramatically among different patient cohorts. Females, East Asians, non-smokers, and patients with adenocarcinoma usually show higher response rates. Meanwhile, a number of biological factors are also associated with EGFR-TKIs responsiveness. In order to better understand the predictive value of these biomarkers and their significance in clinical application we prepared this brief review. Here we mainly focused on EGFR somatic mutations, MET amplification, K-ras mutations, EGFRvIII mutation, EGFR gene dosage and expression, HER2 gene dosage and expression, and Akt phosphorylation. We think EGFR somatic mutation probably is the most effective molecular predictor for EGFR-TKIs responsiveness and efficacy. Mutation screening test can provide the most direct and valuable guidance for clinicians to make decision on EGFR-TKIs therapy.
KW - EGFR
KW - Gene amplification
KW - Non-small cell lung cancer
KW - Somatic mutation
KW - Tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=48149108067&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=48149108067&partnerID=8YFLogxK
U2 - 10.7150/ijms.5.209
DO - 10.7150/ijms.5.209
M3 - Review article
C2 - 18645621
AN - SCOPUS:48149108067
SN - 1449-1907
VL - 5
SP - 209
EP - 217
JO - International journal of medical sciences
JF - International journal of medical sciences
IS - 4
ER -